跳至主要内容
临床试验/TCTR20230131004
TCTR20230131004已完成2 期

A randomized controlled trial to evaluate the efficacy and safety of Clears-belong Plus in participants with long COVID (COVID-19)

Rangsit University0 个研究点目标入组 66 人开始时间: 2023年1月31日最近更新:
适应症

试验速览

阶段
2 期
状态
已完成
入组人数
66

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
20 Years 至 N/A (No limit)(—)
性别
All

入选标准

  • 1. Thai males and females aged 20 years old or above.
  • 2. Previously had COVID-19 infection as confirmed by ATK or RT-PCR at least 4 weeks before screening.
  • 3. Long COVID diagnosis as confirmed by a physician.
  • 4. Willing to attend all the study procedures.

排除标准

  • 1. Have or suspected to have penumonitis
  • 2. Have at least one of the following conditions: chronic obstructive pulmonary disease, chronic lung diseases, chronic renal disease, cardiovascular diseases, cerebrovascular diseases, congenital heart diseases, psychotic disorders, hepatitis, cirrhosis, and immunodeficiency disorders
  • 3. Current use of warfarin or benzodiazepines
  • 4. Positive result from tetrahydrocannabinol (THC) urine test at screening
  • 5. Positive result from urine pregnancy test at screening
  • 6. Plan to become pregnant or breastfeeding
  • 7. History of hypersensitivity to any active ingredients of Clears-belong Plus
  • 8. Participating in other studies
  • 9. Any other health conditions that could interfere with participation in this study based on investigator's judgement

研究者

相似试验